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was developed and administered with the support of the main Italian OAT patients’ 
association. Returned questionnaires were checked for consistence and valid data were 
summarised. Travelling costs and earning losses were evaluated according to published 
prices. RESULTS: A total of 4722 valid questionnaires were returned from all over 
Italy. The prevalent OAT management model in this sample relies on hospital-based 
anticoagulation clinics. Patients incur signiﬁcant transportation, earning loss, and 
other out-of pocket costs at an estimated mean overall monthly cost of about a30. 
The distribution of costs in the population is wide, and depends mainly on monitoring 
frequency, home-clinic distance, and employment status. CONCLUSIONS: This study 
contributes to clarify the organisational models of the Italian OAT population and 
delivers data on patients’ costs that may be used when evaluating alternative manage-
ment options.
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OBJECTIVES: The Hellenic Society for Pharmacoecnomics and Outcomes Research 
(HELSPOR) assessed the effectiveness of recent policy reforms on controlling phar-
maceutical expenditure in Greece. METHODS: The latest available data on pharma-
ceutical expenditure in Greece derived from the National Statistical Service (NSS) were 
analyzed for the period of 2000–2007. RESULTS: Pricing and reimbursement systems 
implemented in Greece have been based on cost-containment rather than economic 
evaluation criteria. Cost containment policies introduced in the past (positive reim-
bursement list, pricing at the lowest EU price) had limited or no effect. In 2006, the 
reimbursement list was abolished and currently all marketed prescription medicines 
are reimbursed by Social Insurance. This, however, does not appear to be a sustainable 
system, as Insurance Funds exhibit signiﬁcant deﬁcits and hospitals incur enormous 
debts (in December 2008, hospital debt towards pharmaceutical companies was a2.66 
billion, exhibiting a remarkable increase within a year (38.3%)). Although two laws 
have been voted to introduce a reimbursement system that would replace the positive 
list, none has yet been implemented. The outcome of the past and current pharmaceuti-
cal policies in Greece has been the increase of pharmaceutical expenditure. Pharma-
ceutical expenditure rose to a 4.5 billion in 2007, accounting for 21.6% of total health 
care expenditure and 2% of GDP. Pharmaceutical expenditure increased over the 
period 2000–2007 at a mean annual growth rate (MAGR) of 13.4%, a rate higher 
than total health care expenditure (10.3%). CONCLUSIONS: Pharmaceutical policy 
reforms have increased expenses for Insurance Funds and hospitals. Implementation 
of economic evaluation criteria could be a start for rational decision making and cost 
containment in the pharmaceutical sector.
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OBJECTIVES: Despite the availability of Hungarian methodological guidelines the 
quality of economic evaluations submitted in pharmaceutical reimbursement dossiers 
are rather heterogeneous. The 10–12 point international critical appraisal checklists 
are not detailed enough to ﬁlter the problems occurring in Hungarian studies, therefore 
they are not widely used. As a consequence only small proportion of economic evalu-
ations are published in medical journals, which limits the development of health eco-
nomic skills and the broad utilisation of economic rationale in medical decision-making. 
The aim of our study was to develop a relevant Hungarian checklist for the critical 
appraisal of economic evaluations. METHODS: Fifty economic evaluations submitted 
for reimbursement of pharmaceuticals in 2007–8 were scrutinized by two independent 
reviewers to identify the most common methodological problems. Reviewers had no 
intention to revise previous reimbursement decisions. Based upon the assessment of 
10 studies, a draft checklist was developed. After assessing 25 reports, an extended 
workshop was settled to reconcile the opinion of reviewers and to improve the check-
list. The reviewers scrutinized the second 25 economic evaluations according to the 
checklist. The checklist was ﬁnalized at a second workshop. RESULTS: The ﬁnal 
checklist consists of 3–8 dichotomised questions in several major topics concerning 
comparator selection, effectiveness, costs, sensitivity analysis, methodological 
approach and interpretation of results. When the checklist is used for critical appraisal, 
reviewers may exclude non-relevant question items. CONCLUSIONS: Our checklist 
is based on current Hungarian practice. As the published checklist will be ofﬁcially 
used for the appraisal of economic evaluations in reimbursement dossiers, submitters 
can assure the quality of their economic evaluations and predict outcomes of the 
health technology assessment process. The transparent method of single technology 
assessment may improve the consistency of pharmaceutical reimbursement decisions 
and the utilization of economic evaluations in other ﬁelds of health care 
decision-making.
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OBJECTIVES: To determine whether there is a relationship between pharmaceutical 
consumption and health care results. This issue is of highest importance in the French 
political debate, France being one of the countries in Europe with the highest phar-
maceutical consumption and related expenses. METHODS: The levels of health care 
status of seven European countries (France, Denmark, Germany, Italy, Spain, Sweden 
and the UK) are compared through a range of indicators coming from sources (OECD, 
Eurostat, WHO) or scientiﬁc publications and systematically analyzed in comparison 
with health care and pharmaceutical expenses in each country. The analysis ﬁrst relies 
on global health care indicators such as life expectancy, life expectancy without dis-
ability and mortality rates by causes. A focus is then made on the two major causes 
of death in Europe: cancer and cardiovascular diseases. Analysis is conducted on 2004 
data. RESULTS: The highest life expectancy at 65, both for men and women, is posi-
tively correlated with the level of pharmaceutical consumption and expenses. Several 
studies (OMS) have suggested the high level of performance of the French health care 
system. The rather low level of life expectancy at birth for men is mostly the results 
of high mortality rates for external causes (suicides, injuries), independent from the 
health care system. Low mortality rates for cardiovascular diseases are associated with 
good management of risk factors through pharmaceutical treatments (hypolipidemic 
drugs). Regarding cancer, good results in terms of survival rates at ﬁve years are 
associated with a level of drug consumption high in value but more moderate in 
volume, this suggesting the use of innovating products. CONCLUSIONS: While it is 
not possible to demonstrate a ﬁrm cause-to-effect relationship between the relatively 
high investment in health care and the relatively better health care status in France 
compared with its European neighbours, a range of facts and ﬁgures do converge in 
support of this hypothesis.
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OBJECTIVES: The purpose of this study was to characterize the drugs in short supply 
in the American market on or before June 1, 2009 and to determine if certain char-
acteristics affect the duration of drug shortages. METHODS: We examined if the US 
Food and Drug Administration’s policy of identifying which drugs in short supply are 
“medically necessary” is effective in reducing the length of those shortages and if the 
market concentration (the number of manufacturers) of a drug is associated with the 
length of its shortage. Medical drug shortages create disruptions for buyers such as 
hospitals and pharmacies. They can affect public health, especially when the drug has 
few or no alternatives and can be considered medically necessary. We compiled pub-
licly-available data from the American Society of Health-Systems Pharmacists (ASHP) 
and the Food and Drug Administration (FDA) to determine the lengths of shortages, 
whether each drug had been deemed “medically necessary” by the FDA, and the 
number of active or defunct manufacturers for each drug. Using that data, we per-
formed statistical analyses to test two null hypotheses: 1) that there is no association 
between a drug in short supply being labeled “medically necessary” by the FDA and 
the length of its shortage; and 2) that there is no association between the number of 
manufacturers for a drug in short supply and the length of its shortage. RESULTS: 
We failed to reject our null hypotheses for both active shortages and resolved shortage 
drugs as listed by the ASHP on June 1, 2009. CONCLUSIONS: These results suggest 
that the FDA’s policy of determining which in-shortage drugs are “medically neces-
sary” did not reduce the duration of those shortages. The ﬁndings also indicate the 
number of manufacturers for a particular drug or device in short supply is not associ-
ated with the length of its shortage.
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OBJECTIVES: On the 1st of May 2004 Hungary—together with many European 
countries—joined to the European Union which resulted in several changes in the 
Hungarian legislation. In the coverage policy of pharmaceuticals, the Directive 89/105/
EEC of the Council of the European Communities on Transparency was implemented 
Hungary in order to provide regulation on decision on drug prices. The aim of our 
study is to calculate the average delay of decision-making on pharmaceutical reim-
bursement. METHODS: The data derive from the drug reimbursement database of 
the National Health Insurance Fund Administration (OEP) of Hungary covering the 
4 year period of 2005–2008. We calculated the delay as the time between the submis-
sion of application by the manufacturer and the ﬁrst day of reimbursement of drug. 
Our analysis covered drugs submitted within the frame of simpliﬁed procedure, drugs 
submitted in the normal procedure were omitted. RESULTS: Between 2005–2008 the 
total number of applications was 519, 440, 399, 377; while the average delay was 94, 
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95, 62, 55 days respectively. Most of the application represented new generic drugs 
(252, 213, 264, 225 pieces). Between 2005–2008 the average delay for new generic 
drugs was 75, 64, 58, 56 days. CONCLUSIONS: The introduction of EU transparency 
directive provided a strong regulatory framework for decision-making process on drug 
reimbursement. In the simpliﬁed procedure we did not found signiﬁcant differences 
in time delay of decision according to submission categories. However, in 2007 the 
average delay signiﬁcantly decreased compared to previous years.
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OBJECTIVES: This study aims to conduct a descriptive analysis of the policy environ-
ment surrounding the generic medicines retail market in Portugal. The policy analysis 
focuses on supply-side measures (i.e. market access, pricing, reference-pricing and 
reimbursement of generic medicines) and demand-side measures (i.e. incentives for 
physicians to prescribe, for pharmacists to dispense and for patients to use generic 
medicines). METHODS: The policy analysis was based on an international literature 
review. Also, a simulation exercise was carried out to compute potential savings from 
substituting generic for originator medicines in Portugal using IMS Health data. 
RESULTS: Portugal has developed a successful generic medicines market by increasing 
reimbursement of generic medicines (until October 2005), by introducing a reference-
pricing system, by encouraging physicians to prescribe by international non- 
proprietary name (INN), and by allowing generic substitution by pharmacists. 
However, the development of the generic medicines market has been hindered by the 
existence of copies, pricing regulation, certain features of the reference-pricing system, 
weak incentives for physicians to prescribe generic medicines and a ﬁnancial disincen-
tive for pharmacists to dispense generic medicines. Increased generic substitution 
would be expected to reduce public expenditure on originator medicines by 45%. 
CONCLUSIONS: The development of the Portuguese generic medicines market has 
mainly been fuelled by supply-side measures. To support the further expansion of the 
market, policy makers need to strengthen demand-side measures inciting physicians 
to prescribe, pharmacists to dispense and patients to use generic medicines.
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OBJECTIVES: Biologic agents have helped revolutionize the treatment of a number 
of chronic and acute diseases. These highly valued products have also placed a signiﬁ-
cant cost burden on health care systems. For example, the average annual price of 
TNFs in the EU5 is a12,400 per patient (MSP). Payers, understandably, are eagerly 
awaiting the arrival of biosimilars. However, because of their biologic nature, biosimi-
lars are not exact copies of the drugs they seek to emulate. This important difference 
between biosimilars and traditional generics has resulted in greater requirements for 
regulatory approval and has led some markets to take positions on their (non) inter-
changeability. Given these dynamics, this research explores likely price discounts of 
anticipated biosimilars, provides an analysis of what lessons can be taken from tradi-
tional generics and forecasts how biosimilars might change the standard of care for 
their respective therapy areas. METHODS: Review the EMEA data requirements and 
current prices of biosimilars on the European market. Review current biosimilar 
environment, including a review of current biosimilar pricing and uptake. Limited 
primary research. RESULTS: The most commonly anticipated price discount of 
biosimilars is 20–30% to the parent drug. This expectation is largely driven by past 
experience with biosimilar human growth hormones, erythropoietins and G-CSFs. 
CONCLUSIONS: Biosimilars will introduce a new competitive dynamic to the bio-
logic market. However, because of the considerably higher cost of bringing biosimilars 
to market and the potential to differentiate biosimilars, the initial price discount of 
biosimilars will be more similar to a me-too like pricing strategy as opposed to what 
has been seen with competitive generic markets (e.g. ﬂuoxetine). Importantly, even at 
a 20–30% discount, there will be sufﬁcient cost-savings to encourage the use of 
biosimilars over their parent drug.
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OBJECTIVES: To prepare detailed analysis of parallel trade of pharmaceuticals in 
Poland and to build a model calculating direct and indirect savings resulting from this 
phenomenon. METHODS: Diligent analysis of parallel trade based on data provided 
by IMS Health and gathered from The Polish Ofﬁce for Registration of Medical 
Products, Medical Devices and Biocidal Products preceded by systematic literature 
review. RESULTS: Parallel import (PI) of pharmaceuticals in Poland has been possible 
since Poland became an EU member in May 2004. Since that date the PI licences have 
been granted for 352 medicines in Poland (73% prescription medicines, 20% OTC, 
5% hospital and 2% veterinary). Currently, there are 18 parallel traders operating on 
the Polish market although only 5 have a signiﬁcant share. Pharmaceuticals offered 
by parallel importers in Poland are exported mainly from Greece (33%), the Czech 
Republic (17%), France (12%), and the UK (12%). The share of parallel trade in total 
pharmaceutical market reached 0.5% in January 2009 compared to 0.3% in Decem-
ber 2007. The sales value from parallel import was PLN 82 million in 2008. Available 
analyses prove that medicines from parallel trade are cheaper than original products 
in Poland by about 20 to 60%. Up to now, there were no scientiﬁc studies of savings, 
resulting from parallel import in Poland. Detailed study on this topic is planned in 
cooperation with recognized European experts on parallel trade—University of South-
ern Denmark researchers. CONCLUSIONS: Parallel import is expected to grow in 
the next few years in Poland. Therefore, it is necessary to implement a reliable model 
of support for parallel importers by means of appropriate directives introduced by the 
Polish Government. In order to convince decision-makers that parallel import could 
be a source of substantial savings a detailed study is going to be conducted according 
to methodology mentioned above.
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OBJECTIVES: Diffusion of electronic patient record (EPR) systems is almost universal 
in ambulatory medical services in Israel. The drug prescription module of the most 
widely-used EPR system has an intervention capacity of electronically notifying physi-
cians about generic or therapeutic drug substitutions. This notiﬁcation is triggered 
when the physician’s ﬁrst choice of a prescribed drug does not meet preferences of the 
health maintenance organization (HMO). The objective of this paper was to study 
whether and how such an intervention can inﬂuence physicians’ drug prescription 
habits and help contain costs. METHODS: We monitored system use for 40 consecu-
tive weeks in the second largest HMO in Israel, covering more than 1.2 million pre-
scriptions, and recorded physicians’ willingness to comply and prescribe a substitute 
drug in response to the system’s notiﬁcation. RESULTS: Findings show that electronic 
notiﬁcations about substitutes can change physicians’ drug prescription habits toward 
compliance with HMO preferences. Higher physician compliance was found for 
generic substitutes than for therapeutic substitutes. Moreover, compliance was based 
on a cognitive decision process triggered upon notiﬁcation. Examining the notiﬁcation 
and deciding whether to comply or not lasted 2 to 5 seconds, hence not time consum-
ing. An increase in compliance over time, until stabilization, was also observed. The 
direct ﬁnancial savings on drug expenditures were estimated at 4.7%, mostly for 
chronic drugs, implying long-term saving. CONCLUSIONS: The results show that 
embedding notiﬁcations about substitute drugs in an EPR’s drug prescription module 
can be effective and impact drug prescription behavior toward compliance, yet this 
compliance is context-dependent rather than automatic. In addition, long-term cost 
containment can be achieved without decreasing the quality of care.
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OBJECTIVES: In Korea, Positive List System(PLS) was introduced as a drug listing 
system in Jan 2007. This study aimed to comparatively analyze the impact of the PLS 
introduction on the listing of incrementally modiﬁed drugs(IMD) and new drugs(ND). 
METHODS: Database for new drug coverage assessment was established based on 
selective drug listing assessment data from HIRA website and MOHW reference 
publications. They analyzed the two-year drug listing data submitted to the Drug 
Review and Evaluation Committee (2007.1.2008.12) since the introduction of PLS. 
SAS version 9.1 was used for descriptive analysis and logistic regression in statistical 
analysis. RESULTS: After the introduction of PLS, success rate of coverage decision 
was 74.6% and 50.6% for IMD and ND, respectively; for drug price agreement rate, 
73.6% and 85.0%; for ﬁnal drug listing rate, 54.9% and 43.0%, placing IMD higher 
than ND. Time to coverage decision for IMD and ND was 109.0days and 155.7days, 
respectively; time to drug listing was 192.9days and 260.0days, respectively, indicating 
much shorter time to decision and listing for IMD than general ND. The ﬁnal listing 
rate was 52.1% for multinational pharmaceutical companies while being 48.6% for 
domestic drug makers. The factors having the largest inﬂuence on insurance listing 
were cost-effectiveness for IMD and ﬁnancial impact for ND. CONCLUSIONS: The 
introduction of PLS resulted in higher coverage rate and shorter time to ﬁnal listing 
for IMD compared to ND. The factors affecting the insurance listing differed between 
IMD and MD, with cost-effectiveness being the major factor for IMD.
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OBJECTIVES: Recent advances in embryonic stem cell based therapies are moving 
regenerative medicine based products into clinical trials and closer to entering the 
pharmaceutical arena. As these therapies edge closer to entering the market, it is 
important that appropriate health technology assessments are in place to deal with 
these new market entrants. Both autologous and allogenic products are under develop-
ment, however, this analysis will focus on allogenic products and the challenges they 
will face. Allogenic products are derived from cells or tissues and likely to be marketed 
“off the shelf,” similar to conventional biopharmaceutical products. While regulatory 
